News
BMS bags first approval for myeloma CELMoD Zenbexus
Bristol Myers Squibb's CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma.
News
FDA cites 'significant concerns' with ADC lymphoma trial
ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.
News
Manufacturing issues mar ITM's radiopharma filing, says FDA
ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.
News
Ex-BioNTech execs launch 'AI-native' cancer company
Two senior executives formerly at BioNTech have launched a new biotech, Bios Life, that they call "an AI-native cancer surveillance company."
News
Sobi adds rare lymphoma drug with $580m Innate tie-up
Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
